Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States.
| Revenue (Most Recent Fiscal Year) | $1.19B |
| Net Income (Most Recent Fiscal Year) | $2.00M |
| PE Ratio (Current Year Earnings Estimate) | 10.77 |
| PE Ratio (Trailing 12 Months) | 7.26 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.46 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 6.82 |
| Pre-Tax Margin (Trailing 12 Months) | 0.00% |
| Net Margin (Trailing 12 Months) | -4.02% |
| Return on Equity (Trailing 12 Months) | -97.29% |
| Return on Assets (Trailing 12 Months) | 15.74% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.88 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.72 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.37 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-2.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.41 |
| Earnings per Share (Most Recent Fiscal Year) | $1.66 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.31 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 137.88M |
| Free Float | -- |
| Market Capitalization | $1.71B |
| Average Volume (Last 20 Days) | 0.79M |
| Beta (Past 60 Months) | 0.98 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 60.33% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |